Doximity Extends 13-Year U.S. News Partnership; Supports Long-Term Data Revenue
Oct 13, 2026, 12:12 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Positive, but largely non-material; reinforces revenue stability from existing licensing deals and broadens usage of DOCS data within U.S. News' ecosystem, which could modestly support valuation and investor sentiment without new guidance.
AI summary
What happened, with direct paths to the underlying reporting
Doximity (DOCS) announced the extension of its 13-year partnership with U.S. News & World Report, reinforcing its role as a data provider for Doctor Finder, Expert Opinion, and Patient Connect. The deal underscores steady, data-driven revenue from licensing and services and signals continued access to a large physician network and 65 million annual U.S. News users.
Doximity extends 13-year U.S. News partnership; data licensing remains core.
Doximity supplies Expert Opinion surveys, Doctor Finder, and Patient Connect data.
U.S. News site serves more than 65 million people annually.
Doximity network spans over 3 million providers.
Management cites strategic, data-driven collaboration with long-term revenue potential.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
A new securities-class-action targets Doximity (DOCS), asserting the Newsfeed was overstated as a revenue driver and contributing to a May 2026 revenue miss. The suit, if pursued…
Doximity reported Q1 results with an earnings miss but raised full-year revenue guidance, highlighting stronger AI-driven engagement. Analysts turned more bullish on improving gro…
Doximity delivered a mixed Q4 with soft full-year guidance as the HCP digital pharma ad market faces policy and macro headwinds. Management guides modest growth at or below 5% thi…
Doximity's Q4 earnings missed expectations, prompting significant analyst downgrades and lower future revenue guidance. The stock is struggling at a new 52-week low, indicating on…